clinical trial · NCT06399757
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Colorectal CancerCholangiocarcinomaAppendiceal AdenocarcinomaPancreatic AdenocarcinomaGastric AdenocarcinomaEndometrial AdenocarcinomaTriple Negative Breast CancerOvarian CancerAPL-5125
brief summary
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
started
Jun 18, 2024
primary completion
Apr 1, 2027
completion
May 1, 2027
last updated
Jan 7, 2026
official title
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol